ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
Robert C. Sergott(Wills Eye Hospital), Johan van Beek(Biogen (Switzerland)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Thomas Plitz(Merck Serono (Switzerland)), Jeffrey L. Bennett(University of Colorado Denver), Ulrich Freudensprung(Merck Serono (Switzerland)), Daniel D. Mikol(Cardiome (Canada))
Cited by 81
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k